Monograph

L01FA01 - Rituximab

Not porphyrinogenic

Rationale

No CYP affinity. No conceivable effects on PXR activation. However, side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Chemical description

Rituximab is a chimeric human-murine anti-human antigen CD20 monoclonal antibody.

Therapeutic characteristics

Rituximab is used, alone or as part of combination therapy, in the treatment of non-Hodgkins lymphomas. It is administered as an intravenous infusion. Common adverse reactions of rituximab that can be confused with an acute porphyric attack are vomiting, nausea, obstipation, abdominal pain, dorsal pain, anxiety, agitation, insomnia and tachycardia. Side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Hepatic exposure

Metabolism and pharmacokinetics

Rituximab is metabolized as endogenous IgG. Non-CYP metabolism.

IPNet drug reports

No.

References

#	Citation details	PMID
*	Drug reference publications
1.	McEvoy GK, editor. Rituximab. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (10.05.10).
2.	Sweetman SC, editor. Martindale: The complete drug reference. Rituximab. Pharmaceutical Press 2009.
*	Summary of Product Characteristics
3.	Norwegian medicines agency. Summary of Product Characteristics (SPC). Mabthera.

Citation details

PMID

Drug reference publications

McEvoy GK, editor. Rituximab. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (10.05.10).

Sweetman SC, editor. Martindale: The complete drug reference. Rituximab. Pharmaceutical Press 2009.

Summary of Product Characteristics

Norwegian medicines agency. Summary of Product Characteristics (SPC). Mabthera.

Similar drugs

Explore alternative drugs in similar therapeutic classes L01F / L01FA or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands

Blitzima · Blitzima 100 mg, concentraat voor oplossing voor infusie · Blitzima 500 mg concentraat voor oplossing voor infusie · Mabthera · Mabthera 100 mg · Mabthera 1400 mg, Oplossing voor subcutane injectie · Mabthera 500 mg · Rixathon · Rixathon 100 mg, concentraat voor oplossing voor infusie · Rixathon 500 mg, concentraat voor oplossing voor infusie · Riximyo · Riximyo 100 mg, concentraat voor oplossing voor infusie · Riximyo 500 mg, concentraat voor oplossing voor infusie · Ruxience · Ruxience 100 mg, concentraat voor oplossing voor infusie · Ruxience 500 mg, concentraat voor oplossing voor infusie · Truxima · Truxima 100 mg, concentraat voor oplossing voor infusie · Truxima 500 mg, concentraat voor oplossing voor infusie

Belgium

Blitzima · Blitzima 100 mg sol. perf. (à diluer) i.v. flac. · Blitzima 500 mg sol. perf. (à diluer) i.v. flac. · MabThera · MabThera 1 400 mg sol. inj. s.c. flac. · MabThera 1 600 mg sol. inj. s.c. flac. · MabThera 100 mg sol. perf. (à diluer) i.v. flac. · MabThera 500 mg sol. perf. (à diluer) i.v. flac. · Rixathon · Rixathon 100 mg sol. perf. (à diluer) i.v. flac. · Rixathon 500 mg sol. perf. (à diluer) i.v. flac. · Riximyo · Riximyo 100 mg sol. perf. (à diluer) i.v. flac. · Riximyo 500 mg sol. perf. (à diluer) i.v. flac. · Truxima · Truxima 100 mg sol. perf. (à diluer) i.v. flac. · Truxima 500 mg sol. perf. (à diluer) i.v. flac.

United Kingdom

MabThera · MabThera 100mg/10ml concentrate for solution for infusion vials · MabThera 1400mg/11.7ml solution for injection vials · MabThera 500mg/50ml concentrate for solution for infusion vials · Rituximab (MabThera) · Rituximab (MabThera) 1000mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (MabThera) 500mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (MabThera) 600mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (MabThera) 700mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (MabThera) 800mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (MabThera) 900mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (Rixathon) · Rituximab (Rixathon) 1000mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (Rixathon) 500mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (Rixathon) 600mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (Rixathon) 700mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (Rixathon) 800mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (Rixathon) 900mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (Truxima) · Rituximab (Truxima) 1000mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (Truxima) 500mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (Truxima) 700mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (Truxima) 800mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (Truxima) 900mg/500ml in Sodium chloride 0.9% infusion bags · Rituximab (Truxima) 600mg/500ml in Sodium chloride 0.9% infusion bags · Rixathon · Rixathon 100mg/10ml concentrate for solution for infusion vials · Rixathon 500mg/50ml concentrate for solution for infusion vials · Ruxience · Ruxience 100mg/10ml concentrate for solution for infusion vials · Ruxience 500mg/50ml concentrate for solution for infusion vials · Truxima · Truxima 100mg/10ml concentrate for solution for infusion vials · Truxima 500mg/50ml concentrate for solution for infusion vials

Denmark